Ozempic (semaglutide), a GLP-1 receptor agonist licensed for type 2 diabetes treatment in the UK, lists dizziness as an uncommon side effect in the MHRA-approved Summary of Product Characteristics
In addition to regulating blood glucose, these drugs slow down digestion, particularly the emptying of the stomach, as well as sending increased satiety signals to the brain, resulting in lower food intake
Despite Ozempic sharing its active ingredient with some weight loss drugs, it is solely approved for type 2 diabetes and not for weight management
Reach Out to a GP or Private Provider If you havent noticed any changes to your hunger levels while taking semaglutide, dont be afraid to reach out to your GP or the private provider who prescribed your medication
If you are someone with a history of GI sensitivity or who has previously struggled with side effects from other medications, semaglutide may be the more tolerable option despite its lower efficacy ceiling